Aventis returns Picovir to ViroPharma:
This article was originally published in Pharmaceutical Approvals Monthly
You may also be interested in...
Formycon and partner Bioeq have offered further details on timing for the submission of their FYB201 proposed ranibizumab biosimilar version of Lucentis in Europe, the US and elsewhere.
The fresh cash injection will fund Phase II studies evaluating the UK firm's 12-month treatment for diabetic macular edema.
The EU has just become the world’s biggest buyer of COVID-19 vaccines – and wants to make that purchasing power count in 2021 and beyond.